Replies to post #133712 on Biotech Values

[DewDiligence]

I completely agree and the reason why I (and likely most) were hoping MNTA could get mC approved on a fully interchangeable basis prior to inking a deal.

That might have lessened investors’ interchangeability skepticism to some degree, but much of it would likely have remained.

It’s not unreasonable for investors to be somewhat skeptical of MNTA’s lofty goals with respect to FoB's. If MNTA can pull this off, it will rank as one of the greatest technical achievements in the history of the biotech industry, IMHO.